-+ 0.00%
-+ 0.00%
-+ 0.00%

ALTIMMUNE - PEMVIDUTIDE MEETS FDA-RECOGNIZED REGISTRATIONAL ENDPOINTS IN PHASE 2 TRIAL

路透·07/28/2026 11:00:01

登錄查看新聞詳情